Evotec SE (EVO)
USD 4.16
(1.71%)
USD 4.16
(1.71%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 175.05 Million EUR | 0.57% |
| 2022 | 174.06 Million EUR | 14.86% |
| 2021 | 151.54 Million EUR | 20.52% |
| 2020 | 125.74 Million EUR | -5.38% |
| 2019 | 132.89 Million EUR | 18.64% |
| 2018 | 112.01 Million EUR | 35.67% |
| 2017 | 82.56 Million EUR | 41.01% |
| 2016 | 58.55 Million EUR | 54.14% |
| 2015 | 37.98 Million EUR | 29.3% |
| 2014 | 29.37 Million EUR | -5.91% |
| 2013 | 31.22 Million EUR | 0.64% |
| 2012 | 31.02 Million EUR | -11.32% |
| 2011 | 34.98 Million EUR | 43.7% |
| 2010 | 24.34 Million EUR | 32.16% |
| 2009 | 18.42 Million EUR | 4.45% |
| 2008 | 17.63 Million EUR | 119.82% |
| 2007 | 8.02 Million EUR | -65.04% |
| 2006 | 22.95 Million EUR | 8.63% |
| 2005 | 21.12 Million EUR | 991.09% |
| 2004 | 1.93 Million EUR | -45.81% |
| 2003 | 3.57 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 15.74 Million EUR | -54.71% |
| 2024 Q1 | 34.75 Million EUR | -7.72% |
| 2023 Q1 | 53.23 Million EUR | -35.44% |
| 2023 Q2 | 46.32 Million EUR | -12.99% |
| 2023 Q4 | 37.66 Million EUR | -0.42% |
| 2023 FY | 175.05 Million EUR | 0.57% |
| 2023 Q3 | 37.82 Million EUR | -18.35% |
| 2022 Q3 | 28.42 Million EUR | -8.01% |
| 2022 Q1 | 32.29 Million EUR | -37.98% |
| 2022 Q2 | 30.89 Million EUR | -4.33% |
| 2022 Q4 | 82.45 Million EUR | 190.13% |
| 2022 FY | 174.06 Million EUR | 14.86% |
| 2021 FY | 151.54 Million EUR | 20.52% |
| 2021 Q2 | 25.62 Million EUR | -16.48% |
| 2021 Q1 | 30.67 Million EUR | -16.07% |
| 2021 Q3 | 43.16 Million EUR | 68.47% |
| 2021 Q4 | 52.07 Million EUR | 20.63% |
| 2020 FY | 125.74 Million EUR | -5.38% |
| 2020 Q4 | 36.55 Million EUR | 1.19% |
| 2020 Q3 | 36.12 Million EUR | 82.51% |
| 2020 Q2 | 19.79 Million EUR | -40.51% |
| 2020 Q1 | 33.27 Million EUR | -2.38% |
| 2019 Q1 | 31.65 Million EUR | 11.75% |
| 2019 Q4 | 34.08 Million EUR | -2.65% |
| 2019 Q3 | 35 Million EUR | 8.9% |
| 2019 Q2 | 32.14 Million EUR | 1.56% |
| 2019 FY | 132.89 Million EUR | 18.64% |
| 2018 Q2 | 31.8 Million EUR | 72.03% |
| 2018 Q4 | 28.32 Million EUR | -15.2% |
| 2018 FY | 112.01 Million EUR | 35.67% |
| 2018 Q1 | 18.48 Million EUR | -17.9% |
| 2018 Q3 | 33.4 Million EUR | 5.02% |
| 2017 Q3 | 23.03 Million EUR | 26.36% |
| 2017 FY | 82.56 Million EUR | 41.01% |
| 2017 Q4 | 22.51 Million EUR | -2.24% |
| 2017 Q2 | 18.23 Million EUR | -2.93% |
| 2017 Q1 | 18.78 Million EUR | 54.44% |
| 2016 Q2 | 13.53 Million EUR | 8.52% |
| 2016 Q3 | 20.38 Million EUR | 50.66% |
| 2016 Q4 | 12.16 Million EUR | -40.36% |
| 2016 FY | 58.55 Million EUR | 54.14% |
| 2016 Q1 | 12.47 Million EUR | 5.53% |
| 2015 Q2 | 9.14 Million EUR | 38.05% |
| 2015 Q4 | 11.81 Million EUR | 13.6% |
| 2015 FY | 37.98 Million EUR | 29.3% |
| 2015 Q1 | 6.62 Million EUR | -47.9% |
| 2015 Q3 | 10.4 Million EUR | 13.78% |
| 2014 Q2 | 7.17 Million EUR | 55.6% |
| 2014 Q4 | 12.71 Million EUR | 160.76% |
| 2014 FY | 29.37 Million EUR | -5.91% |
| 2014 Q1 | 4.61 Million EUR | -51.87% |
| 2014 Q3 | 4.87 Million EUR | -32.08% |
| 2013 Q3 | 11.08 Million EUR | 81.78% |
| 2013 Q2 | 6.09 Million EUR | 36.96% |
| 2013 Q1 | 4.45 Million EUR | -41.62% |
| 2013 FY | 31.22 Million EUR | 0.64% |
| 2013 Q4 | 9.58 Million EUR | -13.56% |
| 2012 Q1 | 6.53 Million EUR | 6.91% |
| 2012 Q3 | 8.6 Million EUR | 4.24% |
| 2012 Q4 | 7.62 Million EUR | -11.4% |
| 2012 FY | 31.02 Million EUR | -11.32% |
| 2012 Q2 | 8.25 Million EUR | 26.46% |
| 2011 Q3 | 14.43 Million EUR | 69.97% |
| 2011 Q1 | 5.95 Million EUR | -18.09% |
| 2011 Q4 | 6.1 Million EUR | -57.68% |
| 2011 FY | 34.98 Million EUR | 43.7% |
| 2011 Q2 | 8.49 Million EUR | 42.7% |
| 2010 Q3 | 5.82 Million EUR | -22.56% |
| 2010 Q1 | 3.72 Million EUR | -48.71% |
| 2010 FY | 24.34 Million EUR | 32.16% |
| 2010 Q2 | 7.52 Million EUR | 101.8% |
| 2010 Q4 | 7.26 Million EUR | 24.68% |
| 2009 Q2 | 4.07 Million EUR | 36.82% |
| 2009 Q3 | 4.09 Million EUR | 0.47% |
| 2009 Q4 | 7.27 Million EUR | 77.56% |
| 2009 FY | 18.42 Million EUR | 4.45% |
| 2009 Q1 | 2.97 Million EUR | -63.04% |
| 2008 Q4 | 8.05 Million EUR | 35.99% |
| 2008 FY | 17.63 Million EUR | 119.82% |
| 2008 Q3 | 5.92 Million EUR | 294.99% |
| 2008 Q2 | 1.5 Million EUR | -30.28% |
| 2008 Q1 | 2.15 Million EUR | -36.73% |
| 2007 Q4 | 3.4 Million EUR | 137.12% |
| 2007 Q3 | 1.43 Million EUR | -81.03% |
| 2007 Q2 | 7.56 Million EUR | 0.0% |
| 2007 Q1 | - EUR | -100.0% |
| 2007 FY | 8.02 Million EUR | -65.04% |
| 2006 Q3 | 1.69 Million EUR | -40.69% |
| 2006 FY | 22.95 Million EUR | 8.63% |
| 2006 Q4 | 34.05 Million EUR | 1910.04% |
| 2006 Q1 | 2.04 Million EUR | -10.53% |
| 2006 Q2 | 2.85 Million EUR | 39.72% |
| 2005 Q4 | 2.28 Million EUR | 0.0% |
| 2005 Q1 | 506.05 Thousand EUR | 43.37% |
| 2005 Q2 | 541.81 Thousand EUR | 7.06% |
| 2005 Q3 | - EUR | -100.0% |
| 2005 FY | 21.12 Million EUR | 991.09% |
| 2004 Q2 | 537.81 Thousand EUR | 1.01% |
| 2004 FY | 1.93 Million EUR | -45.81% |
| 2004 Q1 | 532.44 Thousand EUR | 285.4% |
| 2004 Q3 | - EUR | -100.0% |
| 2004 Q4 | 352.97 Thousand EUR | 0.0% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | 3.57 Million EUR | 0.0% |
| 2003 Q4 | -287.19 Thousand EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 59.35% |
| PainReform Ltd. | -15 Thousand USD | 1167106.667% |
| Alvotech | -69.42 Million USD | 352.155% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 46.331% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 42.663% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -488.367% |
| Journey Medical Corporation | 52.52 Million USD | -233.297% |
| Dynavax Technologies Corporation | 182.11 Million USD | 3.88% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -139.576% |
| Bright Green Corporation | -237.01 Thousand USD | 73956.195% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 64.298% |
| Embecta Corp. | 749.9 Million USD | 76.657% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1999.142% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1999.142% |
| SCYNEXIS, Inc. | 124.51 Million USD | -40.584% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -4076.664% |
| Silver Spike Investment Corp. | 8.1 Million USD | -2060.43% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -31499.308% |
| Alpha Teknova, Inc. | 10.29 Million USD | -1600.185% |
| Safety Shot Inc | -74.45 Thousand USD | 235203.483% |
| Procaps Group, S.A. | 239.56 Million USD | 26.931% |
| Cosmos Health Inc. | 4.34 Million USD | -3924.56% |
| Theratechnologies Inc. | 62.12 Million USD | -181.754% |
| Harrow Health, Inc. | 90.55 Million USD | -93.313% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -3589.168% |
| Biofrontera Inc. | 16.62 Million USD | -952.812% |
| DURECT Corporation | 6.83 Million USD | -2462.597% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 66.577% |
| Cronos Group Inc. | 6.99 Million USD | -2403.985% |
| OptiNose, Inc. | 62.35 Million USD | -180.737% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 60.32% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 57872.607% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -5631.535% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 43.494% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -3144.98% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -422.76% |
| Radius Health, Inc. | 307.71 Million USD | 43.112% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -1636.982% |
| ProPhase Labs, Inc. | 16.23 Million USD | -977.967% |
| Phibro Animal Health Corporation | 312.48 Million USD | 43.981% |
| Procaps Group S.A. | 239.56 Million USD | 26.931% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -13344.777% |
| Viatris Inc. | 6.43 Billion USD | 97.281% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1911.156% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -220.688% |
| SIGA Technologies, Inc. | 122.09 Million USD | -43.376% |
| Tilray Brands, Inc. | 223.35 Million USD | 21.625% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -318.282% |
| Shineco, Inc. | 882.16 Thousand USD | -19743.272% |
| PetIQ, Inc. | 252.74 Million USD | 30.739% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 23578.248% |
| Incannex Healthcare Limited | 12 Thousand USD | -1458658.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 90.524% |
| Alimera Sciences, Inc. | 61.17 Million USD | -186.171% |
| Assertio Holdings, Inc. | 125.04 Million USD | -39.986% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 2570221.862% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -2570.088% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 7362.997% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -545.54% |
| Hempacco Co., Inc. | -1.21 Million USD | 14497.619% |
| Talphera, Inc. | -4.89 Million USD | 3676.118% |
| Alvotech | -69.42 Million USD | 352.155% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 21.032% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 75.329% |
| Currenc Group, Inc. | 17.35 Million USD | -908.573% |
| Kamada Ltd. | 52.59 Million USD | -232.842% |
| Indivior PLC | 907 Million USD | 80.7% |
| Evoke Pharma, Inc. | 4.97 Million USD | -3415.962% |
| Flora Growth Corp. | 17.73 Million USD | -886.87% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 7362.997% |
| Evolus, Inc. | 140.52 Million USD | -24.568% |
| HUTCHMED (China) Limited | 453.55 Million USD | 61.404% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 49.108% |
| Akanda Corp. | 111.44 Thousand USD | -156968.255% |